-
公开(公告)号：US20240189357A1
公开(公告)日：2024-06-13
申请号：US18552727
申请日：2022-04-14
发明人： Katy REZVANI , Elizabeth SHPALL , Rafet BASAR , May DAHER , Sunil ACHARYA , Nadima UPRETY , Ana Karen NUNEZ CORTES , Emily ENSLEY , David MARIN COSTA
IPC分类号： A61K35/17 , A61K39/00 , A61K45/06 , A61P35/00 , C07K14/54 , C07K16/28 , C12N5/0783 , C12N9/22
CPC分类号： A61K35/17 , A61K39/4613 , A61K39/4631 , A61K39/464429 , A61K39/46444 , A61K45/06 , A61P35/00 , C07K14/5443 , C07K16/2896 , C12N5/0646 , C12N9/22 , A61K2239/13 , A61K2239/17 , A61K2239/21 , A61K2239/48 , C12N2310/20
摘要： Embodiments of the disclosure include methods and compositions related to targeting of CD5-expressing cells with particular engineered receptors. In specific embodiments, NK cells are specifically engineered to bind the CD5 antigen using particular chimeric antigen receptor constructs. In certain embodiments, vectors that express the CD5-targeting CARs also express particular a suicide gene and/or one or more particular cytokines.
-
公开(公告)号：US20230383257A1
公开(公告)日：2023-11-30
申请号：US18248193
申请日：2021-10-15
发明人： Elizabeth SHPALL , Katy REZVANI , Bijender KUMAR , Mayela MENDT , Vahid AFSHAR-KHARGHAN , Rafet BASAR
CPC分类号： C12N5/0644 , A61K35/19 , C12N2506/1369 , C12N2502/11 , C12N2501/727 , C12N2501/125 , C12N2501/145 , C12N2501/2306 , C12N2501/724
摘要： Embodiments of the disclosure include systems, methods, and compositions for producing megakaryocytes and platelets for recipient individuals in need thereof. The megakaryocytes and platelets are produced following co-culture of MSCs and CD34+ cells in media comprising stem cell factor, thrombopoietin, and IL-6, and wherein at least the CD34+ cells have a knock-in of HLA-E at the beta-2-microglobulin genomic locus, in specific embodiments. In some cases, ROCK inhibitors are utilized.
-
公开(公告)号：US20220378739A1
公开(公告)日：2022-12-01
申请号：US17755881
申请日：2020-11-25
发明人： Katy REZVANI , Mayra SHANLEY , Elizabeth SHPALL , David MARIN COSTA , Rafet BASAR , Hila SHAIM
IPC分类号： A61K31/395 , A61K35/17 , C12N5/0783
摘要： Embodiments of the disclosure provide methods and compositions that facilitate cancer treatment including at least because they concern therapies that circumvent the tumor microenvironment. In specific embodiments, compositions are utilized for therapy that utilize NK cells that are protected from the direct inhibition of their activity (using TGF-beta inhibitors) and/or that are indirectly protected from TGF-beta (using integrin inhibitors). In specific embodiments, the NK cells have deficient expression and/or activity for TGF-beta Receptor 2 and/or glucocorticoid receptor.
-
4.发明申请公开(公告)号：US20180353544A1
公开(公告)日：2018-12-13
申请号：US15579330
申请日：2016-06-06
发明人： Katy REZVANI , Elizabeth SHPALL , Enli LIU
IPC分类号： A61K35/17 , A61P35/02 , C07K14/725 , C07K14/47 , C07K14/705 , C07K16/28 , A61P37/06
CPC分类号： A61K35/17 , A61K31/4525 , A61K31/675 , A61K2300/00 , A61P35/02 , A61P37/06 , C07K14/4748 , C07K14/7051 , C07K14/70521 , C07K16/28 , C07K2319/02 , C07K2319/03
摘要： The present invention concerns methods of treating a disease such as leukemia in a subject by administering natural killer (NK) cells. In particular aspects, HLA-C1-licensed KIR2DL2/3 and KIR2DS2 NK cells are administered to a subject with an HLA-C genotype either homozygous or heterozygous for the C1 allele, or HLA-C2 licensed cells are administered to a subject with an HLA-C genotype homozygous for the C2 allele. In further aspects, the NK cells are genetically modified to express a chimeric antigen receptor and interleukin 15.
-
公开(公告)号：US20240125765A1
公开(公告)日：2024-04-18
申请号：US18547401
申请日：2022-03-16
IPC分类号： G01N33/50 , A61K39/00 , C12N5/0783
CPC分类号： G01N33/5005 , A61K39/4613 , A61K39/4631 , C12N5/0646 , C12N2510/00
摘要： Embodiments of the disclosure concern methods and compositions related to optimization of selection of cord blood units to produce immune cells, such as NK cells, for adoptive cell therapy use. In specific embodiments, particular characteristics of the cord blood units and/or characteristics of cells derived therefrom are analyzed. When a threshold measurement for one or more characteristics is met for the cord blood unit(s) and/or characteristics of cells derived therefrom, the cord blood unit(s) are utilized as a source for production of immune cells. Specific characteristics for measurement include cord blood cell viability, total nuclear cell recovery, and nucleated red blood cell content, each prior to cryopreservation, and optionally cytotoxicity and/or expansion of immune cells subsequent to cryopreservation.
-
公开(公告)号：US20230210902A1
公开(公告)日：2023-07-06
申请号：US17997148
申请日：2021-05-11
发明人： Katy REZVANI , Elizabeth SHPALL , Rafet BASAR , David MARIN COSTA , Nadima UPRETY , Emily ENSLEY
IPC分类号： A61P31/14 , A61K45/06 , C07K16/10 , A61K35/17 , C12N5/0783 , C12N15/11 , C12N9/22 , C12N15/90
CPC分类号： A61K35/17 , A61K45/06 , A61P31/14 , C07K16/10 , C12N5/0638 , C12N9/22 , C12N15/11 , C12N15/907 , C12N2310/20 , C12N2501/998 , C12N2501/2302 , C12N2501/2304 , C12N2501/2307 , C12N2501/2315 , C12N2501/2321 , C12N2800/80
摘要： Embodiments of the disclosure includes methods of producing viral-specific therapy (VST) cells specific for the SARS-CoV-2 virus and uses of the cells. The methods may utilized peptide mixtures and stimulation of mononuclear cells using particular cytokine cocktails. The cells may also be genetically modified to lack expression of one or more endogenous genes, including one or more genes that renders the cells more effective and/or able to withstand deleterious conditions, such as the presence of glucocorticoids.
-
公开(公告)号：US20240336699A1
公开(公告)日：2024-10-10
申请号：US18750233
申请日：2024-06-21
发明人： Sonny Oon ANG , Enli LIU , Elizabeth SHPALL , Katy REZVANI
IPC分类号： C07K16/28 , A61K35/17 , A61K38/00 , A61K39/00 , A61P37/06 , C07K14/54 , C07K14/705 , C07K14/71 , C07K14/725 , C12N15/52 , C12N15/86
CPC分类号： C07K16/2896 , A61K35/17 , A61P37/06 , C07K14/5443 , C07K14/70503 , C07K14/7051 , C07K14/70521 , C07K14/71 , C07K16/2803 , C07K16/2863 , C12N15/52 , C12N15/86 , A61K38/00 , A61K2039/5156 , A61K2039/5158 , A61K2039/572 , C07K2317/24 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2319/02 , C07K2319/03 , C07K2319/30 , C07K2319/33
摘要： Provided herein are chimeric antigen receptors (CARs) comprising a truncated EGFRvIII (Ev3) in the hinge region of the CAR and/or a humanized scFv. Further provided herein are immune cells expressing the CARs as well as methods of their use in the treatment of immune disorders.
-
8.发明公开公开(公告)号：US20230220351A1
公开(公告)日：2023-07-13
申请号：US18000414
申请日：2021-06-24
发明人： Elizabeth SHPALL , Katy REZVANI , Mayela MENDT
CPC分类号： C12N5/0669 , C12N5/0605 , A61K35/28 , C12N2501/24 , C12N2501/25 , C12N2501/2301 , C12N2501/2317 , C12N2510/00
摘要： Embodiments of the disclosure encompass systems, methods, and compositions for producing exosomes from primed mesenchymal stem cells that are expanded in the presence of IFNγ, TNFα, IL-1β, and IL-17. The systems, methods, and compositions ay occur in an automated cell expansion system that allows for controllable parameters and from which cells and exosomes may be harvested at one or more times as part of a particular regimen. In specific embodiments, the exosomes may be provided to an individual in need thereof, including in some cases when the exosomes comprise one or more therapeutic agents.
-
公开(公告)号：US20230074303A1
公开(公告)日：2023-03-09
申请号：US17904408
申请日：2021-03-25
发明人： Katy REZVANI , Mayra SHANLEY , David MARIN COSTA , Hila SHAIM , Elizabeth SHPALL
摘要： Embodiments of the disclosure encompass compositions comprising immune effector cells, such as natural killer (NK) cells, where the cells comprise one or more exogenously provided interleukins (IL), and wherein the cell optionally comprises one or more engineered receptors. In specific embodiments, the IL is not IL-15, and is IL-12, IL-21, or both. The NK cells may be utilized for treatment of cancer of any kind, including at least glioblastoma.
-
公开(公告)号：US20220288121A1
公开(公告)日：2022-09-15
申请号：US17638601
申请日：2020-08-25
发明人： Katy REZVANI , Enli LIU , Elizabeth SHPALL , Rafet BASAR , David MARIN COSTA
IPC分类号： A61K35/17 , A01N1/02 , C12N5/0783 , A61K35/545 , A61K35/28 , A61K35/15
摘要： Provided herein are cryopreservation compositions and methods for cells of any kind, including for cells for adoptive cell therapy that are off-the-shelf cells. The cells for cryopreservation may be expanding NK cells expressing chimeric antigen receptors. In specific cases, the cryopreservation media comprises a cryoprotectant, such as DMSO, glycerol or hydroxyethol starch; serum or a non-serum alternative, such as platelet lysate; and one or more cytokines that are either natural, modified, synthetic, or recombinant.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.025 秒)
